1. Home
  2. FUSB vs LUNG Comparison

FUSB vs LUNG Comparison

Compare FUSB & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First US Bancshares Inc.

FUSB

First US Bancshares Inc.

N/A

Current Price

$15.75

Market Cap

91.4M

Sector

Finance

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

SELL

Current Price

$1.88

Market Cap

97.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
FUSB
LUNG
Founded
1952
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.4M
97.1M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
FUSB
LUNG
Price
$15.75
$1.88
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $3.40
AVG Volume (30 Days)
6.3K
★ 262.1K
Earning Date
10-28-2026
10-28-2026
Dividend Yield
★ 1.70%
N/A
EPS Growth
N/A
★ 7.64
EPS
★ 0.64
N/A
Revenue
N/A
★ $90,497,000.00
Revenue This Year
N/A
$0.06
Revenue Next Year
N/A
$8.58
P/E Ratio
$25.77
★ N/A
Revenue Growth
N/A
★ 8.01
52 Week Low
$12.15
$1.13
52 Week High
$16.99
$2.89

Technical Indicators

Market Signals
Indicator
FUSB
LUNG
Relative Strength Index (RSI) 52.22 41.98
Support Level $15.75 $1.20
Resistance Level $16.92 $2.12
Average True Range (ATR) 0.21 0.10
MACD 0.00 -0.01
Stochastic Oscillator 84.37 27.19

Price Performance

Historical Comparison
FUSB
LUNG

About FUSB First US Bancshares Inc.

First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement accounts, and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: